Date: 2012-05-15
Type of information: Production agreement
Compound: Excellagen® (high molecular weight fibrillar bovine Type I topical gel (2.6%) specifically engineered as an adjunct to debridement for the management of diabetic foot ulcers and other dermal wounds)
Company: Angel Biotechnology (UK) Cardium Therapeutics (USA)
Therapeutic area: Metabolic diseases - Cardiovascular diseases
Type agreement: manufacturing
production
supply
Action mechanism:
Disease: diabetic foot ulcers and other dermal wounds
Details: Angel Biomedical Limited, a subsidiary of the biopharmaceutical contract manufacturer Angel Biotechnology has announced an agreement with Cardium Therapeutics. The contract value will cover the manufacture of formulated collagen for Cardium\'s Excellagen® product, which has recently been cleared for marketing by the FDA last March.
In addition to the manufacturing of Excellagen®\'s formulated collagen, Angel Biomedical will assist Cardium to facilitate filing for a CE Mark for Excellagen® for marketing and sale in the European Union and in other countries recognizing CE Mark approval.
Additionally, Angel Biomedical will assist Cardium in establishing its own Device Master File with the FDA\'s Center for Devices and Radiological Health covering the process for manufacturing the Company\'s Excellagen formulated fibrillar collagen gel.
Financial terms: The contract value will be in excess of £400,000 over the initial 12 month period.
Latest news:
